NCT06580665 - Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

August 11, 2030

Conditions

Non-small Cell Lung Cancer

Interventions

PROCEDURE

Cryoablation

Patients undergo cryoablation.

DRUG

Serplulimab

Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Trial Locations (5)

200030

Shanghai Chest Hospital, Shanghai

Unknown

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

The First Affiliated Hospital of Nanchang University, Nanchang

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors

collaborator

Shanghai Henlius Biotech Co., Ltd.

UNKNOWN

collaborator

AccuTarget MediPharma (Shanghai) Co., Ltd

UNKNOWN

lead

Shanghai Chest Hospital

OTHER